NO2016019I1 - Oritavancin og farmasøytisk aksepterbare salter derav - Google Patents

Oritavancin og farmasøytisk aksepterbare salter derav

Info

Publication number
NO2016019I1
NO2016019I1 NO2016019C NO2016019C NO2016019I1 NO 2016019 I1 NO2016019 I1 NO 2016019I1 NO 2016019 C NO2016019 C NO 2016019C NO 2016019 C NO2016019 C NO 2016019C NO 2016019 I1 NO2016019 I1 NO 2016019I1
Authority
NO
Norway
Prior art keywords
oritavancin
pharmaceutically acceptable
acceptable salts
salts
pharmaceutically
Prior art date
Application number
NO2016019C
Other languages
English (en)
Other versions
NO2016019I2 (no
Original Assignee
The Medicines Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41722337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2016019(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Medicines Co filed Critical The Medicines Co
Publication of NO2016019I1 publication Critical patent/NO2016019I1/no
Publication of NO2016019I2 publication Critical patent/NO2016019I2/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NO2016019C 2008-08-30 2016-10-11 Oritavancin og farmasøytisk aksepterbare salter derav NO2016019I2 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9331408P 2008-08-30 2008-08-30
US9349708P 2008-09-02 2008-09-02
PCT/US2009/055466 WO2010025438A2 (en) 2008-08-30 2009-08-29 Methods of treatment using single doses of oritavancin

Publications (2)

Publication Number Publication Date
NO2016019I1 true NO2016019I1 (no) 2016-10-11
NO2016019I2 NO2016019I2 (no) 2019-01-25

Family

ID=41722337

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2016019C NO2016019I2 (no) 2008-08-30 2016-10-11 Oritavancin og farmasøytisk aksepterbare salter derav

Country Status (18)

Country Link
US (2) US8420592B2 (no)
EP (2) EP3006038B1 (no)
JP (1) JP5782615B2 (no)
CN (2) CN102215858A (no)
AU (1) AU2009285564B2 (no)
CA (1) CA2736860C (no)
DK (2) DK3006038T3 (no)
EA (1) EA020490B1 (no)
ES (1) ES2570401T3 (no)
FI (1) FI3006038T3 (no)
HU (2) HUE027373T2 (no)
MX (1) MX2011002249A (no)
NL (1) NL300834I2 (no)
NO (1) NO2016019I2 (no)
NZ (1) NZ591525A (no)
PL (1) PL2337575T3 (no)
PT (1) PT3006038T (no)
WO (1) WO2010025438A2 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3006038B1 (en) * 2008-08-30 2024-07-03 The Medicines Company Single doses of oritavancin for treating or preventing a bacterial infection
CA2760159C (en) * 2009-04-28 2021-01-12 Thomas Parr, Jr. Methods of treating bacterial infections using oritavancin
US20150246024A1 (en) * 2012-08-20 2015-09-03 The University Of Chicago Methods and compositions for inhibiting gram positive bacteria
WO2014176068A2 (en) * 2013-04-22 2014-10-30 The Medicines Company Treatment and prevention of bacterial skin infections using oritavancin
PL3038616T3 (pl) 2013-08-26 2023-08-07 Melinta Therapeutics, Inc. Metody leczenia bakteriemii i zapalenia kości i szpiku z zastosowaniem orytawancyny
WO2015031579A2 (en) * 2013-08-28 2015-03-05 The Medicines Company Methods for treating bacterial infections using oritavancin and polymyxins
US20170119793A1 (en) * 2014-06-12 2017-05-04 Cem-102 Pharmaceuticals, Inc. Compositions and methods for treating bone and joint infections
CA2955256C (en) 2014-07-17 2023-02-14 The Medicines Company High purity oritavancin and method of producing same
AU2017221435A1 (en) * 2016-02-18 2018-09-06 Melinta Therapeutics, Inc. Oritavancin formulations
US20200171124A1 (en) * 2016-04-15 2020-06-04 Lupin Limited Topical compositions for ophthalmic and otic use
CN108409837B (zh) 2018-03-06 2021-09-24 上海来益生物药物研究开发中心有限责任公司 一组具有抗耐药性细菌活性的糖肽类化合物、其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840684A (en) 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
US5994297A (en) * 1997-08-22 1999-11-30 Eli Lilly And Company Therapy for Staphylococcus aureus
TR200103211T2 (tr) * 1999-05-03 2002-02-21 Eli Lilly And Company Streptococcus pneumoniae enfeksiyonlarının tedavisi.
SI1278549T1 (sl) 2000-05-02 2009-04-30 Theravance Inc Sestavek, ki vsebuje ciklodekstrin in glikopeptidni antibiotik
US20030176327A1 (en) * 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
CA2487094A1 (en) * 2002-05-28 2003-12-11 Becton, Dickinson And Company Methods for in vitro expansion and transdifferentiation of human pancreatic acinar cells into insulin-producing cells
AU2003274927A1 (en) 2002-08-23 2004-03-11 Genome Therapeutics Corporation Methods and reagents for preventing bacteremias
US20040127403A1 (en) * 2002-09-06 2004-07-01 Francesco Parenti Methods for treating and preventing Gram-positive bacteremias
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
CA2664444C (en) 2006-09-25 2015-10-27 Targanta Therapeutics Corp. Use of oritavancin for prevention and treatment of anthrax
EP3006038B1 (en) * 2008-08-30 2024-07-03 The Medicines Company Single doses of oritavancin for treating or preventing a bacterial infection
CA2760159C (en) * 2009-04-28 2021-01-12 Thomas Parr, Jr. Methods of treating bacterial infections using oritavancin
WO2015031579A2 (en) * 2013-08-28 2015-03-05 The Medicines Company Methods for treating bacterial infections using oritavancin and polymyxins

Also Published As

Publication number Publication date
EA020490B1 (ru) 2014-11-28
PL2337575T3 (pl) 2016-09-30
CN102215858A (zh) 2011-10-12
NZ591525A (en) 2014-03-28
EP2337575B1 (en) 2016-04-13
AU2009285564A1 (en) 2010-03-04
WO2010025438A9 (en) 2010-05-14
EP3006038B1 (en) 2024-07-03
FI3006038T3 (fi) 2024-08-12
CA2736860A1 (en) 2010-03-04
PT3006038T (pt) 2024-08-23
HUS1600039I1 (hu) 2016-11-28
EP3006038A1 (en) 2016-04-13
NO2016019I2 (no) 2019-01-25
EP2337575A4 (en) 2012-10-17
US20110201546A1 (en) 2011-08-18
JP2012501349A (ja) 2012-01-19
DK2337575T3 (en) 2016-05-23
HUE027373T2 (hu) 2016-09-28
EP2337575A1 (en) 2011-06-29
AU2009285564B2 (en) 2014-05-22
EA201100413A1 (ru) 2012-01-30
WO2010025438A2 (en) 2010-03-04
DK3006038T3 (da) 2024-08-26
US8420592B2 (en) 2013-04-16
CA2736860C (en) 2020-04-28
US20130172237A1 (en) 2013-07-04
MX2011002249A (es) 2011-06-24
JP5782615B2 (ja) 2015-09-24
NL300834I2 (no) 2016-11-16
ES2570401T3 (es) 2016-05-18
CN106620649A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
NO2017033I2 (no) baricitinib og farmasøytisk akseptable salter derav
NO2016019I1 (no) Oritavancin og farmasøytisk aksepterbare salter derav
NO2019010I1 (no) Eravasyklin eller farmasøytisk akseptable salter derav
NL301176I2 (nl) Tepotinib en farmaceutisch aanvaardbare solvaten en zouten daarvan
NO2016014I2 (no) ceritinib eller farmasøytisk akseptable salter derav
NO2017036I1 (no) Daklatasvir og farmasøytisk akseptable salter derav, spesielt daklatasvir dihydroklorid
NL300891I2 (nl) Lotilaner en zouten daarvan
DK2437762T3 (da) Kunstige tårer og terapeutiske anvendelser
NL301214I2 (nl) Lasmiditan en farmaceutisch aanvaardbare zouten daarvan
DK2344478T3 (da) Cc-1065 analoger og deres konjugater
IL211042A0 (en) Imidazopyridin-2-one derivatives and uses thereof
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
DK3092901T3 (da) Quinolonanaloger og fremgangsmåder relateret dertil
FI20085334A0 (fi) Harjoitusmenetelmä ja -järjestelmä
ZA201103635B (en) Azaquinolinone derivatives and uses thereof
EP2377154A4 (en) INTERCONNECT HOLE STRUCTURE AND ASSOCIATED METHOD
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
IL210755A0 (en) Devices and methods for forming tracts in tissue
BR112012010242A2 (pt) derivados de heteroarilpiperidina e heteroarilpiperazina
DK2160336T3 (da) Forbindelsesmekanisme og fremgangsmåde
EP2440053A4 (en) BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF
IL208771A0 (en) Iminopyridine derivatives and use thereof
GB0817121D0 (en) Anti-fungal therapy
BRPI0818598A2 (pt) agentes terapêuticos - 802
DK2406372T3 (da) Prægastrisk esterase og derivater deraf